AbbVie presented new data from real-world studies showing VRAYLAR (cariprazine) significantly improves depressive symptoms, functioning, and quality of life in adults with major depressive disorder (MDD) and bipolar I (BP-I) depression. These studies confirm that the benefits seen in clinical trials translate to everyday clinical practice, where patients often have complex treatment needs. The findings support VRAYLAR's use as an effective adjunctive therapy, with common side effects including nausea and dizziness. This real-world evidence may help clinicians make more informed treatment decisions for patients with mood disorders.
AbbVie Inc (ABBV) shares are trading at USD 262.50 with a slight 0.57% decline as of Sep 18, 2026 19:43 WIB on Pluang. Despite the new real-world data supporting VRAYLAR's effectiveness in mood disorders, the stock shows a high sell activity of 93% on the platform. This reflects cautious investor sentiment even as AbbVie highlights promising treatment benefits.
AbbVie announced that its investigational drug etentamig met the dual primary endpoints of objective response rate and progression-free survival in a Phase 3 study for relapsed/refractory multiple myeloma. The results were presented at the 23rd Inter...
At the 2026 Science of Skin Summit, Allergan Aesthetics, an AbbVie company, presented its latest research on aging, regenerative aesthetics, and exosome-based skincare. The company introduced the FACTS Principles, a scientific framework by SkinMedica...
